Evaluation of Outcomes for Veterans With Opioid Use Disorder Managed by a Clinical Pharmacist Practitioner

ABSTRACT Background Opioid use disorder (OUD) has been a growing concern in the United States, and there are significant barriers to accessing timely and consistent treatment. Veterans face disproportionately high rates of OUD, often accompanied by higher rates of mental health disorders and chronic pain. Clinical Pharmacist Practitioners (CPPs) have emerged as key contributors in delivering Medication for Opioid Use Disorder (MOUD) as part of interdisciplinary care teams. The objectives of this study were to determine whether Veterans with OUD managed by a Substance Use Disorder (SUD) CPP have clinical outcomes comparable with those managed by physicians or nurse practitioners (MD/NPs). Methods A single‐center, retrospective cohort study was conducted at the Robley Rex Veterans Affairs Medical Center (RRVAMC). Veterans with MOUD initiated between June 1, 2023 and February 12, 2025 who attended at least three follow‐up appointments were included. Patients were grouped by primary provider (CPP vs. MD/NP). The primary outcome was a composite of nonfatal overdose, OUD‐related hospitalization, and OUD‐related emergency department (ED) visits. Secondary outcomes included individual components of the primary outcome, all‐cause mortality, no‐show rates, active naloxone prescriptions, prescription drug monitoring program (PDMP) screening completion, suicide risk screening completion, and positive urine drug screen (UDS) results. Results Seventy‐seven patients were included (CPP group, n = 34; MD/NP group, n = 43). There was no statistically significant difference in the primary composite outcome between groups. CPPs had statistically significant higher PDMP screening completion rates. No significant differences were noted in other secondary outcomes. Conclusion CPPs provided MOUD care that was safe and effective, with outcomes comparable with those of physicians and nurse practitioners. Their increased use of risk mitigation tools such as PDMP underscores the value of CPP integration into MOUD programs, which can increase access to SUD care.

Authors

Institutions

Publication Details

Journal
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Published
2026-01-14
DOI
https://doi.org/10.1002/jac5.70164
Citations
1
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
41.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of Outcomes for Veterans With Opioid Use Disorder Managed by a Clinical Pharmacist Practitioner

Colleen M. Lewellyan, Christina A. White, William Frizzell, Lydia Jackson et al.
1 citations
JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
Opioid Use Disorder Treatment
41.85
article

Evaluation of Outcomes for Veterans With Opioid Use Disorder Managed by a Clinical Pharmacist Practitioner

Colleen M. Lewellyan, Christina A. White, William Frizzell, Lydia Jackson, Morgan Snyder
article en
1 citations

Abstract

ABSTRACT Background Opioid use disorder (OUD) has been a growing concern in the United States, and there are significant barriers to accessing timely and consistent treatment. Veterans face disproportionately high rates of OUD, often accompanied by higher rates of mental health disorders and chronic pain. Clinical Pharmacist Practitioners (CPPs) have emerged as key contributors in delivering Medication for Opioid Use Disorder (MOUD) as part of interdisciplinary care teams. The objectives of this study were to determine whether Veterans with OUD managed by a Substance Use Disorder (SUD) CPP have clinical outcomes comparable with those managed by physicians or nurse practitioners (MD/NPs). Methods A single‐center, retrospective cohort study was conducted at the Robley Rex Veterans Affairs Medical Center (RRVAMC). Veterans with MOUD initiated between June 1, 2023 and February 12, 2025 who attended at least three follow‐up appointments were included. Patients were grouped by primary provider (CPP vs. MD/NP). The primary outcome was a composite of nonfatal overdose, OUD‐related hospitalization, and OUD‐related emergency department (ED) visits. Secondary outcomes included individual components of the primary outcome, all‐cause mortality, no‐show rates, active naloxone prescriptions, prescription drug monitoring program (PDMP) screening completion, suicide risk screening completion, and positive urine drug screen (UDS) results. Results Seventy‐seven patients were included (CPP group, n = 34; MD/NP group, n = 43). There was no statistically significant difference in the primary composite outcome between groups. CPPs had statistically significant higher PDMP screening completion rates. No significant differences were noted in other secondary outcomes. Conclusion CPPs provided MOUD care that was safe and effective, with outcomes comparable with those of physicians and nurse practitioners. Their increased use of risk mitigation tools such as PDMP underscores the value of CPP integration into MOUD programs, which can increase access to SUD care.

JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACYVol. 9(2)
Louisville VA Medical Center (US)
Good health and well-being
Openalex Percentile: Top 1%
Opioid Use Disorder Treatment
41.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.